Cold-and-vibration device plus screen distraction for children facing needles
TL;DR Needlecalm is a palm-sized device that cools and buzzes the skin near a needle site, and a cartoon on a tablet keeps the child looking the other way. It's built for kids aged 2 to 12 facing blood draws, drips and booster shots. Paediatric clinics, children's hospitals and sample-collection labs are the ones who buy it.
India's immunisation programme reaches about 2.6 crore children a year across roughly 1.2 crore vaccination sessions[1]. The national schedule packs about a dozen injections into the first two years and then adds boosters at 5–6, 10 and 16[2]. Blood tests, IV lines and dental work come on top of that.
And kids hate needles. In a Canadian survey, 63% of children aged 6–17 said they feared needles, a quarter of parents had held their child down for a shot, and about one in twelve families named the fear as the main reason they skipped a vaccine[3]. I couldn't find a comparable Indian survey.
So what does a busy Indian clinic do today? A parent's lap and a quick jab, that's it.
First, the regulatory bit - Needlecalm gives short-term relief of procedural pain and anxiety. It does not diagnose or treat any disease. A powered cold-and-vibration device is likely Class B under the Medical Devices Rules 2017, which means a state manufacturing licence. Confirm the class with CDSCO.
The nurse straps the device a few centimetres above the needle site and cools the skin for about a minute, then switches on vibration during the stick while the child watches a short cartoon picked for their age on a tablet the clinic already owns. Each clinic gets a reusable unit, swappable cold packs and covers.
The seed version combined cooling, vibration and AR glasses. I've dropped the glasses. A pooled analysis found no clear benefit under age 2[4], which is when most Indian vaccine doses happen, and the FDA-cleared VR comparable is approved only for ages 4–11[5]. Pooled trials in children up to 12 do show lower self-reported pain with cold and vibration[6]. So Needlecalm goes after older kids and skips the headset.
The child benefits but the clinic or lab pays. A private paediatric clinic wants calmer vaccine visits and parents who come back. A diagnostic lab collecting children's blood wants fewer failed draws and fewer staff holding a child still. The best-known comparable, a bee-shaped US device, retails for US$44.99 in the US (about ₹4,350)[7]. Parents can also buy a home unit for a child who needs frequent tests.
The FDA created a device category for VR pain relief when it cleared a paediatric VR headset in September 2023[5], so procedural comfort now has a regulatory track. A 2024 meta-analysis of 19 trials with 2,846 children pulled the cold-and-vibration evidence together[6]. Indian children's hospitals and lab chains also compete openly on patient experience now, though I found no data that puts a number on it.
There's no market figure for paediatric procedural-pain devices in India. The narrowest buyer count is the Indian Academy of Pediatrics' 52,194 members[8]. If 10–20% of their practices bought one unit at ₹3,000–5,000 then device sales would total roughly ₹1.5–5 Cr (my estimate).
That's small. Lab chains, hospitals and repeat consumables have to carry the business.
A US product is the original bee-shaped cold-and-vibration device and it's widely studied[6][7]. I couldn't confirm whether it's sold in India or at what price. Another US company sells a clinical VR headset with FDA clearance for needle procedures in children aged 4–11[5].
There's no Indian maker that I could find. The gap is a device designed and priced for Indian clinics and lab collection centres, with distraction content in local languages.
| Difficulty | Moderate (39/100) |
| Starting capital | ₹45–80 L |
| Time to launch | 9–12 months |
The hardware is simple - a motor, a battery and a cold pack. The real work is getting the device classified and licensed, running a small Indian trial that clinics will believe, and selling to clinics that treat a ₹4,000 device as a nice-to-have. Hygiene matters too, since the same device touches many kids a day.
Yes. A powered cold-and-vibration device is likely Class B, so licensing comes before selling.
Building this outside India? The categories above usually have a local equivalent, so check with your own regulator.
Don't trust AI to judge a child's pain or safety. Pain scores come from validated scales and nurses, and Needlecalm only gives short-term relief, it doesn't treat anything.
Want to work out the AI layer for Needlecalm? Talk to Yash →
Here's what can go south -
This is a modest, honest business and it won't become a venture-scale company on its own. It suits a founder with medical-device sales experience and a paediatrician co-founder. Personally, I'd want one lab chain or children's hospital to pay for 50 units after a month-long trial in its collection centres before building anything.
My estimate is ₹45–80 L, covering design, a small study, licensing and the first batch of units. The kit has the line items.
Yes. It's likely a Class B device, so you need a state manufacturing licence, and CDSCO should confirm the class first.
Yes, kids fear needles everywhere. Device approval works differently in each country though, so check with your local regulator first.
The free Needlecalm validation kit has the line-by-line capital breakdown, the effort scoring, the device-licensing checklist, a 14-day validation sprint with pass/fail targets, a 90-day launch plan, 10 interview questions for clinics and labs, and 5 assumptions to test. Download the kit →
Thinking about building Needlecalm or something close to it? The make-or-break bit is finding a buyer with enough needle volume to order in bulk and keep reordering consumables. If you need a hand with that, you know where to find me. Talk to Yash →
For illustration only. Names are fictional and ideas hypothetical; sourced facts are real but may be out of date. Nothing here is legal, financial or professional advice, and Yash Khatri is not personally liable for any use of it. Read the full disclaimer.